Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

3(75%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(1)

Detailed Status

Active, not recruiting2

Completed1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed125%

active_not_recruiting250%

recruiting125%

Recent Activity

3 active trials

Showing 4 of 4

active_not_recruitingphase_1

Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

NCT07044115

completedphase_1

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

NCT04103905

recruitingphase_1

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

NCT04110301

active_not_recruitingphase_1

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

NCT04304040

Clinical Trials (4)

Showing 4 of 4 trials

NCT07044115Phase 1

Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

Active Not Recruiting

NCT04103905Phase 1

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

Completed

NCT04110301Phase 1

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Recruiting

NCT04304040Phase 1

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4